Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ovarian Cancer: early-phase trial registry
147 of 338 indexed Ovarian Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #20 of 28,707 conditions by registered trial count.
338 US clinical trials · 147 currently recruiting · #20 of 28,707 conditions by registered trial count
Ovarian Cancer: 338 US clinical trials tracked, 147 recruiting.
Ovarian Cancer is the subject of 338 registered US clinical trials on ClinicalTrials.gov, 147 of them currently open to new participants. 28 are in Phase 3-4 (later-stage) and 230 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 31 of these trials.
Enrollment posture brief
Registry condition ovarian-cancer
OPEN 147 | RECR 43% | LATE 28 | EARLY 230 | RANK #20 | SPON 31
Volume-matched condition peers
Nearest open-share peer: Cigarette Smoking (43% recruiting · 46 trials)
Ovarian Cancer lists 147 open slots (43% of 338 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ovarian Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ovarian Cancer is recruiting above its size-band peers.
147 of 338 indexed trials (43.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Ovarian Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 31 of 338 trials (9.2%). 186 distinct sponsors appear on at least one study for this condition label.
-
Typical Ovarian Cancer enrolment sits around 86 participants.
Median target enrolment is 86 among the 323 trials that report a genuine target (sentinel values excluded). 172 of those (53.3%) plan for fewer than 100 participants.
-
Ovarian Cancer research is mostly interventional.
297 interventional and 41 observational studies make up this index (87.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
338 total, page 6 of 7
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
National Cancer Institute (NCI)
NCT00001302
A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
Hoffmann-La Roche
NCT03695380
Writing About Experiences With Ovarian Cancer
University of Maryland, College Park
NCT02593422
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
NCT04672460
Gleevec Study for Patients With Ovarian Cancer
M.D. Anderson Cancer Center
NCT00510653
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Mundipharma Research Limited
NCT03345485
A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
Eli Lilly and Company
NCT00190697
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
EMD Serono
NCT01936363
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
CASI pharmaceuticals
NCT01104675
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
Massachusetts General Hospital
NCT01652079
Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
AstraZeneca
NCT02610075
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Dana-Farber Cancer Institute
NCT00520013
Elizabeth Registry for Low Grade Ovarian Cancer
M.D. Anderson Cancer Center
NCT00345709
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
NCT00470366
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
Morphotek
NCT00318370
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
NCT04580485
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
NCT00474994
Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy
Washington University School of Medicine
NCT05427214
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences
NCT03629756
ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study
Memorial Sloan Kettering Cancer Center
NCT04051502
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
Celldex Therapeutics
NCT00709462
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
NYU Langone Health
NCT00005049
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
Eastern Cooperative Oncology Group
NCT00003518
Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin
Memorial Sloan Kettering Cancer Center
NCT00002559
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT02440425
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Memorial Sloan Kettering Cancer Center
NCT00588237
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Benaroya Research Institute
NCT00343044
Yoga Practice for Breast or Ovarian Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT02305498
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
OncoMed Pharmaceuticals
NCT02092363
A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer
Abramson Cancer Center at Penn Medicine
NCT00683241
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer
Massachusetts General Hospital
NCT00181688
Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer
University of Southern California
NCT00003449
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Ronald Buckanovich
NCT03056833
Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families
University of Washington
NCT03119285
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
Gilead Sciences
NCT03558139
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
NCT02262455
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
OncoNano Medicine
NCT03735680
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Robert Morris
NCT00227721
Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
NCT00002734
Vinorelbine and XR9576 to Treat Cancer
National Cancer Institute (NCI)
NCT00001944
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
New Mexico Cancer Research Alliance
NCT01670799
TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT02764333
Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer
Indiana University
NCT00477386
Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity
City of Hope Medical Center
NCT00825201
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Dana-Farber Cancer Institute
NCT00268918
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
Beth Israel Deaconess Medical Center
NCT03532139
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Gynecologic Oncology Group
NCT00003967
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00024258
Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
New Mexico Cancer Research Alliance
NCT02470299
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Dana-Farber Cancer Institute
NCT00545792
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 143 |
| Phase 2 | 87 |
| Phase 3 | 25 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Ovarian Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ovarian Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ovarian Cancer page
338 registered trials, 147 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 147 Ovarian Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Ovarian Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ovarian Cancer condition card totals 338 registered trials; most-linked intervention Bevacizumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.